TFL Gallery / t-end-of-study

t-end-of-study

Discovered on disk but not present in site/config.json.

This display exists on disk but is not registered in site/config.json, so it has no reviewed metadata.

Slug
t-end-of-study
Regulatory ID
Type
Table
E3 position
unassigned
Status
built
Current iteration
v002
Datasets
Evidence
not yet generated
Requirements
Used in

Generated by the same pipeline run that wrote the ARD and the HTML above, from the same rendered cells; the short hash is the manifest's record of the file.

t-end-of-study · post_text variant · study CDISCPILOT01 · data cut-off 2015-03-05

Summary of End of Study Data
Study CDISCPILOT01 — Intent-to-Treat
Placebo (N=86) Xanomeline Low Dose (N=84) Xanomeline High Dose (N=84) Total (N=254) p-value
Completion Status:
   Completed Week 24 [1] 60 (70%) 28 (33%) 30 (36%) 118 (46%) <.0001
   Early Termination (prior to Week 24) 26 (30%) 56 (67%) 54 (64%) 136 (54%)
   Missing 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Reason for Early Termination (prior to Week 24):
   Adverse Event [1] 8 (9%) 44 (52%) 39 (46%) 91 (36%) <.0001
   Death 1 (1%) 1 (1%) 0 (0%) 2 (1%)
   Lack of Efficacy [1][2] 3 (3%) 0 (0%) 1 (1%) 4 (2%) 0.3281
   Lost to Follow-up 1 (1%) 0 (0%) 0 (0%) 1 (0%)
   Subject decided to withdraw 9 (10%) 8 (10%) 8 (10%) 25 (10%)
   Physician decided to withdraw subject 1 (1%) 0 (0%) 2 (2%) 3 (1%)
   Protocol criteria not met 1 (1%) 0 (0%) 2 (2%) 3 (1%)
   Protocol violation 1 (1%) 1 (1%) 1 (1%) 3 (1%)
   Sponsor decision 1 (1%) 2 (2%) 1 (1%) 4 (2%)
   Missing 0 (0%) 0 (0%) 0 (0%) 0 (0%)
[1] Fisher's exact test, comparing the row against the rest of the treatment group across all three groups at once. The statistical analysis plan (section 9.7.1.2) specifies this test for protocol completion, lack of efficacy and adverse event only; the other rows are descriptive and carry no p-value.
[2] Lack of efficacy is based on either patient/caregiver perception or physician perception.
N in the column headers is the number of subjects randomised to that treatment group; every percentage on this table, including the reasons for early termination, is based on it rather than on the number of early terminations — as the reference report does. The reference's own note calls N the number of subjects "entered in study (i.e., signed informed consent)"; this display does not repeat that wording, because 306 subjects were screened and 254 randomised, and it is the 254 that N counts.
The population line above reads Intent-to-Treat because that is what the reference report prints above this table. In this study it selects the same 254 subjects as the whole analysis dataset, since every subject in it carries ITTFL = Y.
Completion status is the study's own COMP24FL and the reason is its DCREASCD. Both are collected fields carried in the CDISC pilot's ADSL; neither exists in the pharmaverse re-derivation of this study, so this display reads the pilot package directly.
Treatment groups are planned (randomised) treatment, TRT01P. In this ADSL planned and actual treatment agree for all 254 subjects.
144 subjects discontinued the study in total; the 136 counted here are those who did so before Week 24. The remaining 8 discontinued after completing Week 24.
The cut-off shown is the latest subject end date (RFENDT) recorded in the vendored ADSL. The CDISC pilot package states no separate database-lock date.
Source: adsl (phuse-org/phuse-scripts, data/adam/cdisc — the CDISC pilot submission's own ADaM package). Data cut-off: 2015-03-05.
open.csr display t-end-of-study (post_text variant); generated from the committed ARD.

Rendered from outputs/t-end-of-study/v002/table.html.

Every iteration is kept: outputs/t-end-of-study/vNNN/ holds the spec snapshot, the ARD, the rendered output, and a manifest recording who regenerated it, why, and from which commit.